NCT01742988View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

October 9, 2020

Study Completion Date

October 9, 2020

Conditions
LymphomaRelapsed LymphomaRefractory LymphomaRelapsed and/or Refractory LymphomaRelapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Double-hit Lymphoma (DHL)Triple-hit Lymphoma (THL)Double-expressor Lymphoma (DEL)High-grade B-cell Lymphoma (HGBL)
Interventions
DRUG

fimepinostat

DRUG

Rituximab

DRUG

venetoclax

Trial Locations (11)

10065

Memorial Sloan-Kettering Cancer Center, New York

19104

Hospital of the University of Pennsylvania, Philadelphia

30322

Winship Cancer Institute, Emory University, Atlanta

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute, Nashville

48109

University of Michigan, Ann Arbor

60637

University of Chicago Medicine, Chicago

73104

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City

77030

MD Anderson Cancer Center, Houston

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

98104

Swedish Cancer Institute, Seattle

All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

lead

Curis, Inc.

INDUSTRY

NCT01742988 - Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | Biotech Hunter | Biotech Hunter